[Federal Register Volume 78, Number 173 (Friday, September 6, 2013)]
[Notices]
[Page 54913]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2013-21735]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Application; 
Clinical Supplies Management, Inc.

    Pursuant to Title 21 Code of Federal Regulations 1301.34 (a), this 
is notice that on July 22, 2013, Clinical Supplies Management, Inc., 
342 42nd Street South, Fargo, North Dakota 58103, made application by 
renewal to the Drug Enforcement Administration (DEA) to be registered 
as an importer of Sufentanil (9740), a basic class of controlled 
substance listed in schedule II.
    The company plans to import the listed controlled substance with 
the sole purpose of packaging, labeling, and distributing to customers 
which are qualified clinical sites, conducting FDA-approved clinical 
trials.
    Any bulk manufacturer who is presently, or is applying to be, 
registered with D listed in schedule II, which falls under the 
authority of section 1002(a)(2)(B) of the Act 21 U.S.C. 952 (a)(2)(B) 
may, in the circumstances set forth in 21 U.S.C. 958(i), file comments 
or objections to the issuance of the proposed registration and may, at 
the same time, file a written request for a hearing on such application 
pursuant to 21 CFR 1301.43, and in such form as prescribed by 21 CFR 
1316.47.
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than October 7, 2013.
    This procedure is to be conducted simultaneously with, and 
independent of, the procedures described in 21 CFR Sec.  1301.34(b), 
(c), (d), (e), and (f). As noted in a previous notice published in the 
Federal Register on September 23, 1975, 40 FR 43745-46, all applicants 
for registration to import a basic class of any controlled substance in 
schedules I or II are, and will continue to be, required to demonstrate 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, that the requirements for such 
registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 
1301.34(b), (c), (d), (e), and (f) are satisfied.

    Dated: August 29, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2013-21735 Filed 9-5-13; 8:45 am]
BILLING CODE 4410-09-P